<DOC>
	<DOCNO>NCT00119145</DOCNO>
	<brief_summary>Case management one key strategy malaria control endemic country . Plasmodium falciparum malaria become resistant commonly use cheap antimalarial drug chloroquine , amodiaquine , sulfadoxine-pyrimethamine ( SP ) . Thus safety efficacy new anti-malarial drug need test site well-characterised malariometric index order make appropriate treatment policy . Artemisinin-based combination chemotherapy document consistently produce fast relief clinical symptom parasite clearance uncomplicated falciparum malaria currently use antimalarial drug . So far , artesunate-amodiaquine ( AS-AQ ) artemether-lumefantrine ( AR-LM ) two register fixed-dose artemisinin combination chemotherapy produce industrial scale , good manufacturing practice already use Africa . Several African country , include Ghana , therefore introduce either AS-AQ AR-LM first-line antimalarial evaluate case change . Clearly , direct comparison safety efficacy profile two combination different epidemiological condition urgently need guide inform decision appropriate antimalarial first-line treatment regimen . This study aim evaluate efficacy safety artesunate-amodiaquine combination therapy , artemether-lumefantrine , artesunate-lapdap open-labelled , randomised , non-inferiority drug trial . The study result inform future decision first- second-line treatment uncomplicated P. falciparum malaria respect efficacy safety Ghana .</brief_summary>
	<brief_title>Kintampo Trial Combination Therapy Malaria</brief_title>
	<detailed_description>A study fund GMP-LSHTM Kintampo district Ghana currently assess efficacy SP part comprehensive process characterise site pattern seasonal dynamic P. falciparum transmission , infection , morbidity . The initial result study demonstrate high parasitological failure rate ( 18 % ) day 14 treatment , indication SP longer suitable use Ghana . Artesunate combination therapy ( ACTs ) find efficacious safe , produce rapid clearance parasite malaria symptom ; well tolerate . Lapdap newly register , relatively cheap antimalarial short half-life find highly efficacious strict trial condition treatment acute uncomplicated falciparum infection endemic site Africa . Despite rapid clearance lapdap , child treat drug high incidence malaria episode treat SP though haematological adverse effect document common lapdap SP . At present , fixed-dose combination regimens artesunate-amodiaquine ( AS-AQ ) artemether-lumefantrine ( AR-LM ) two register artemisinin combination chemotherapy produce industrial scale , good manufacturing practice already use Africa . Several African country introduce either AS-AQ AR-LM first-line antimalarial evaluate case change . Ghana , change antimalarial drug policy artesunate-amodiaquine combination therapy ( AS-AQ ) first line drug . The selection new ACT drive partly cost treatment , critical look safety efficacy ACTs Ghana yet do . This study aim evaluate efficacy safety artesunate-amodiaquine combination therapy ( AS-AQ ) , Artemether-lumefantrine ( Coartem ) , Artesunate-lapdap ) drug non-inferiority study . Objectives Primary objective : • To evaluate efficacy artesunate-amodiaquine versus artemether-lumefantrine , versus artesunate-lapdap treatment child age 6 month ten year , infect uncomplicated falciparum malaria , paediatric outpatient clinic Kintampo hospital . Secondary objective : • To evaluate safety artesunate-amodiaquine versus artemether-lumefantrine , versus artesunate-lapdap treatment child 6 month ten year uncomplicated falciparum malaria . Study design method Study site : This study conduct Kintampo district middle belt Ghana investigator Kintampo Health Research Centre locate . Kintampo Health Research Centre ( KHRC ) , one three research centre Health Research Unit ( HRU ) Ghana Health Service , Ghana , lie within forest-savannah , transitional ecological zone Brong Ahafo Region Ghana . Study design : This randomise , open-labelled , non-inferiority drug trial . At Kintampo district hospital , 510 paediatric outpatient ( refer sample size calculation ) uncomplicated P. falciparum malaria age 6 month 10 year recruit randomly assign one three study arm : ( ) Artesunate-Amodiaquine ( AS-AQ ) , ( ii ) Artemether-Lumefantrine ( AR-LM ) , ( iii ) Artesunate-lapdap ( AS-LP ) . The classification clinical parasitological response follow relevant WHO protocol area intense transmission . Follow-up , however , extend beyond day 14 day 28 increase sensitivity vivo test . PCR-based genotyping compare pair parasite isolates day 0 day asexual parasite reappearance use distinguish recrudescence re-infection .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>Age 6 month 10 year Body weight &gt; 5 kg Uncomplicated P. falciparum malaria Monoinfection P. falciparum Asexual parasite density 2,000 200,000 parasites/µl Haemoglobin ≥7.0 g/dL Axillary temperature ≥37.5ºC history fever precede 24 hr Ability tolerate oral therapy Residence study area Haemoglobin &lt; 7.0 g/dL Leucocyte count : &gt; 15,000/µL G6PD deficiency Mixed malaria infection Danger sign ( unable drink ; repeat vomiting ; recent history convulsion ; lethargic unconscious state ; unable stand sit ) sign severe malaria define WHO Any severe underlying disease ( cardiac , renal , hepatic disease , malnutrition , know HIV infection ) Concomitant disease mask assessment response , e.g . know suspected hearing impairment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>antimalarial drug</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>trial</keyword>
</DOC>